α-Lipoic Acid Vaginal Administration Contrasts Inflammation and Preterm Delivery in Rats

Simple item page
dc.contributor.authorMicili S.C.
dc.contributor.authorGoker A.
dc.contributor.authorKuscu K.
dc.contributor.authorErgur B.U.
dc.contributor.authorFuso A.
dc.date.accessioned2024-07-22T08:09:09Z
dc.date.available2024-07-22T08:09:09Z
dc.date.issued2019
dc.description.abstractα-Lipoic acid (ALA) is a safe natural molecule involved in the immunomodulation of many physiological processes. Orally administered ALA has been reported to treat several inflammatory pathologies and support pregnancy. Our study aimed at testing ALA vaginal administration in female Wistar rats evaluating its tissue distribution (experiment I), impact on implantation process (experiment II), and effectiveness in contrasting induced preterm birth (experiment III). In experiment I, rats were intravaginally treated with 50 mg/kg or 500 mg/kg ALA, or with a physiologic solution, for 4 days. α-Lipoic acid distribution in uterus and cervical tissues was evaluated by immunohistochemical analyses. In experiment II, rats received intravaginally the above treatments for 5 days, then they were mated and, if pregnant, included in the experiment to evaluate both implantation rate and the content of implantation mediators in uterus tissues. In experiment III, pregnant rats were pretreated with placebo or with vaginal ALA for 4 days and then induced to delivery with mifepristone plus PGE2 on the 19th day of pregnancy. The delivery time was recorded, and the messenger RNA (mRNA) levels of pro-inflammatory cytokines were detected in the uterine tissues by real-time polymerase chain reaction. Immunohistochemistry was also performed. Results showed that vaginal ALA was well absorbed and distributed. The treatment did not affect the implantation process and was able to significantly revert mifepristone plus prostaglandin E2 effects, delaying the timing of delivery and significantly decreasing mRNA synthesis and release of pro-inflammatory cytokines. We provide for the first time new information on vaginal ALA use, even during pregnancy, opening a perspective for further studies. © The Author(s) 2018.
dc.identifier.DOI-ID10.1177/1933719118766266
dc.identifier.issn19337191
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/14688
dc.language.isoEnglish
dc.publisherSAGE Publications Inc.
dc.subjectAdministration, Intravaginal
dc.subjectAnimals
dc.subjectAnti-Inflammatory Agents, Non-Steroidal
dc.subjectCervix Uteri
dc.subjectEmbryo Implantation
dc.subjectFemale
dc.subjectInflammation
dc.subjectInflammation Mediators
dc.subjectPregnancy
dc.subjectPremature Birth
dc.subjectRats, Wistar
dc.subjectThioctic Acid
dc.subjectTissue Distribution
dc.subjectUterus
dc.subjectcytokine
dc.subjectmessenger RNA
dc.subjectmifepristone
dc.subjectplacebo
dc.subjectprostaglandin E2
dc.subjectthioctic acid
dc.subjectautacoid
dc.subjectnonsteroid antiinflammatory agent
dc.subjectthioctic acid
dc.subjectanimal experiment
dc.subjectanimal model
dc.subjectanimal tissue
dc.subjectArticle
dc.subjectcontrolled study
dc.subjectfemale
dc.subjectfemoral artery
dc.subjectimmunohistochemistry
dc.subjectinflammation
dc.subjectmessenger RNA synthesis
dc.subjectnonhuman
dc.subjectobstetric delivery
dc.subjectpregnancy rate
dc.subjectpremature labor
dc.subjectpriority journal
dc.subjectrat
dc.subjectreal time polymerase chain reaction
dc.subjecttissue distribution
dc.subjectuterine cervix
dc.subjectuterus
dc.subjectuterus tissue
dc.subjectanimal
dc.subjectdrug effect
dc.subjectinflammation
dc.subjectintravaginal drug administration
dc.subjectmetabolism
dc.subjectnidation
dc.subjectpregnancy
dc.subjectprematurity
dc.subjectWistar rat
dc.titleα-Lipoic Acid Vaginal Administration Contrasts Inflammation and Preterm Delivery in Rats
dc.typeArticle

Files

Collections

Scopus Koleksiyonu